High-Density Lipoprotein: Vascular Protective Effects, Dysfunction, and Potential as Therapeutic Target
Open accessThe DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
High-density lipoprotein (HDL) is a complex mixture of lipoproteins that is associated with many minor proteins and lipids that influence the function of HDL. Although HDL is a promising marker and potential therapeutic target based on its epidemiological data and the effects of healthy HDL in vitro in endothelial cells and macrophages, as well as based on infusion studies of reconstituted HDL in patients with hypercholesterolemia, it remains still uncertain whether or not HDL cholesterol–raising drugs will improve outcomes. Recent studies suggest that HDL becomes modified in patients with coronary artery disease or acute coronary syndrome because of oxidative processes that result in alterations in its proteome composition (proteome remodelling) leading to HDL dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 2×
“This finding was particularly surprising because HDL-C increased by 80% and LDL-C decreased by 25% as compared with atorvastatin alone.(8) Interestingly, in the RADIANCE 2 (Rating Atherosclerotic Disease Change by Imaging with a New Cholesteryl-EsterTransfer Protein Inhibitor) trial,(94) which used B-mode carotid ultr…”
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011) · Nature Cell Biology · doi:10.1038/ncb2210 · Cited by 2,741
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022 · cited 4×
“However, CRP levels were found to be increased by dalcetrapib treatment in the dal-OUTCOMES trial.10 By contrast, CRP was unaffected by anacetrapib in DEFINE trial; in fact, it tended to be slightly higher in the treatment than in the placebo group.100 As such, it is not surprising that the dal-HEART program was stopp…”
InfluentialCholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707 · cited 1×
“duced coronary plaque volume as assessed by intravascular ultrasound.(68) It is to be noted that no dose–response relationship”
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
The Framingham Study: The Epidemiology of Atherosclerotic Disease
Dawber, T. R. (1980) · Harvard University Press eBooks · doi:10.4159/harvard.9780674492097 · Cited by 1,454
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Effect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., & Tuzcu, E. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070635 · Cited by 966
Cholesterol Efflux and Atheroprotection: Advancing the Concept of Reverse Cholesterol Transport
Rosenson, R. S., Brewer, H. B., Davidson, W. S., Fayad, Z. A., Fuster, V., Goldstein, J., Hellerstein, M., Jiang, X.-C., Phillips, M. C., Rader, D. J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.066589 · Cited by 953 · cited 10×
“The latter 2 processes involve the activity of phospholipid transfer protein.(11,33) The catabolism of HDL differs from that of LDL because only a minor proportion of HDL seems to be eliminated by holoparticle uptake into cells.”
InfluentialSharrett, A. R., Ballantyne, C. M., Coady, S. A., Heiss, G., Sorlie, P. D., Catellier, D., & Patsch, W. (2001) · Circulation · doi:10.1161/hc3501.095214 · Cited by 944
Vaisar, T., Pennathur, S., Green, P. S., Gharib, S. A., Hoofnagle, A. N., Cheung, M. C., Byun, J., Vuletic, S., Kassim, S., Singh, P., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci26206 · Cited by 942 · cited 1×
“HDL particles carry >80 different proteins and hundreds of lipid species.(19,22) Most recently, even microRNAs have been found in HDL particles,(23) although a relevant uptake of microRNAs from HDL into vascular cells was not observed.”
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749
Yuhanna, I. S., Zhu, Y., Cox, B. E., Hahner, L. D., Osborne-Lawrence, S., Lu, P., Marcel, Y. L., Anderson, R. G. W., Mendelsohn, M. E., Hobbs, H. H., et al. (2001) · Nature Medicine · doi:10.1038/89986 · Cited by 742
Tardif, J.-C. (2007) · JAMA · doi:10.1001/jama.297.15.jpc70004 · Cited by 726
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3
Nofer, J.-R., van der Giet, M., Tölle, M., Wolinska, I., von Wnuck Lipinski, K., Baba, H. A., Tietge, U. J., Gödecke, A., Ishii, I., Kleuser, B., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18004 · Cited by 698
HPS2-THRIVE Collaborative Group, Haynes, R., Jiang, L., Hopewell, J. C., Li, J., Chen, F., Parish, S., Landray, M. J., Collins, R., Armitage, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht055 · Cited by 676
Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M
Christoffersen, C., Obinata, H., Kumaraswamy, S. B., Galvani, S., Ahnström, J., Sevvana, M., Egerer-Sieber, C., Muller, Y. A., Hla, T., Nielsen, L. B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103187108 · Cited by 598
Ansell, B. J., Navab, M., Hama, S., Kamranpour, N., Fonarow, G., Hough, G., Rahmani, S., Mottahedeh, R., Dave, R., Reddy, S. T., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103624.14436.4b · Cited by 590
Self-citationFayad, Z. A., Mani, V., Woodward, M., Kallend, D., Abt, M., Burgess, T., Fuster, V., Ballantyne, C. M., Stein, E. A., Tardif, J.-C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61383-4 · Cited by 538
Besler, C., Heinrich, K., Rohrer, L., Doerries, C., Riwanto, M., Shih, D. M., Chroni, A., Yonekawa, K., Stein, S., Schaefer, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42946 · Cited by 535 · cited 5×
“Furthermore, in the mouse carotid artery model, HDL enhances endothelial repair after vascular injury.(27) Finally, HDL obtained from healthy subjects induced expression of Bcl-xL, the endothelial antiapoptotic Bcl-2 protein, and reduced endothelial cell apoptosis in vitro and in apoE-deficient mice in vivo.”
InfluentialSelf-citationIntestinal ABCA1 directly contributes to HDL biogenesis in vivo
Brunham, L. R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27352 · Cited by 519
Rosenson, R. S., Brewer, H. B., Chapman, M. J., Fazio, S., Hussain, M. M., Kontush, A., Krauss, R. M., Otvos, J. D., Remaley, A. T., & Schaefer, E. J. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.155333 · Cited by 511
HDL as a target in the treatment of atherosclerotic cardiovascular disease
Linsel-Nitschke, P., & Tall, A. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1658 · Cited by 486
Bots, M. L., Visseren, F. L., Evans, G. W., Riley, W. A., Revkin, J. H., Tegeler, C. H., Shear, C. L., Duggan, W. T., Vicari, R. M., Grobbee, D. E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61088-5 · Cited by 461
Masoudi, F. A., Inzucchi, S. E., Wang, Y., Havranek, E. P., Foody, J. M., & Krumholz, H. M. (2005) · Circulation · doi:10.1161/01.cir.0000154542.13412.b1 · Cited by 458 · cited 1×
“Furthermore, it seemed that peroxisome proliferator-activated receptor-γ agonists increase the incidence of heart failure because of fluid retention.(85,86) Rosiglitazone has, therefore, been withdrawn from the market.”
Ectopic β-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis
Martinez, L. O., Jacquet, S., Esteve, J.-P., Rolland, C., Cabezón, E., Champagne, E., Pineau, T., Georgeaud, V., Walker, J. E., Tercé, F., et al. (2003) · Nature · doi:10.1038/nature01250 · Cited by 458
High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men
Spieker, L. E., Sudano, I., Hürlimann, D., Lerch, P. G., Lang, M. G., Binggeli, C., Corti, R., Ruschitzka, F., Lüscher, T. F., & Noll, G. (2002) · Circulation · doi:10.1161/01.cir.0000013424.28206.8f · Cited by 438
Zhang, Y., Zanotti, I., Reilly, M. P., Glick, J. M., Rothblat, G. H., & Rader, D. J. (2003) · Circulation · doi:10.1161/01.cir.0000086981.09834.e0 · Cited by 436
Davidson, W. S., Silva, R. A. G. D., Chantepie, S., Lagor, W. R., Chapman, M. J., & Kontush, A. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.186031 · Cited by 415
Sorrentino, S. A., Besler, C., Rohrer, L., Meyer, M., Heinrich, K., Bahlmann, F. H., Mueller, M., Horváth, T., Doerries, C., Heinemann, M., et al. (2010) · Circulation · doi:10.1161/circulationaha.108.836346 · Cited by 402 · cited 2×
“Several of these changes have been associated with a loss of vasoprotective functions, such as loss of the ability to stimulate cholesterol efflux after chlorination or nitration of tyrosine residues in apoA-I,(32) loss of the ability to inhibit endothelial apoptosis,(28) or loss of the ability to induce endothelium-d…”
Self-citationHigh-Density Lipoprotein Function, Dysfunction, and Reverse Cholesterol Transport
Fisher, E. A., Feig, J. E., Hewing, B., Hazen, S. L., & Smith, J. D. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300133 · Cited by 393
Mackey, R. H., Greenland, P., Goff, D. C., Lloyd-Jones, D., Sibley, C. T., & Mora, S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.060 · Cited by 363
Wiesner, P., Leidl, K., Boettcher, A., Schmitz, G., & Liebisch, G. (2009) · Journal of Lipid Research · doi:10.1194/jlr.d800028-jlr200 · Cited by 363
Nofer, J.-R., Levkau, B., Wolinska, I., Junker, R., Fobker, M., von Eckardstein, A., Seedorf, U., & Assmann, G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103782200 · Cited by 359
Self-citationShah, A. S., Tan, L., Long, J. L., & Davidson, W. S. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r035725 · Cited by 351
High-density lipoprotein heterogeneity and function in reverse cholesterol transport
Rothblat, G. H., & Phillips, M. C. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328338472d · Cited by 340
Riwanto, M., Rohrer, L., Roschitzki, B., Besler, C., Mocharla, P., Mueller, M., Perisa, D., Heinrich, K., Altwegg, L., von Eckardstein, A., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.108753 · Cited by 337 · cited 5×
“to the endothelial antiapoptotic effects when HDL of patients with stable CAD, or of patients with ACS, are examined.(25,27,28)”
InfluentialSelf-citationCharacterization of Levels and Cellular Transfer of Circulating Lipoprotein-Bound MicroRNAs
Wagner, J., Riwanto, M., Besler, C., Knau, A., Fichtlscherer, S., Röxe, T., Zeiher, A. M., Landmesser, U., & Dimmeler, S. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300741 · Cited by 325
Self-citationSirtori, C. R., Calabresi, L., Franceschini, G., Baldassarre, D., Amato, M., Johansson, J., Salvetti, M., Monteduro, C., Zulli, R., Muiesan, M. L., et al. (2001) · Circulation · doi:10.1161/01.cir.103.15.1949 · Cited by 322
Clee, S. M., Kastelein, J. J. P., van Dam, M., Marcil, M., Roomp, K., Zwarts, K. Y., Collins, J. A., Roelants, R., Tamasawa, N., Stulc, T., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10727 · Cited by 314
Speer, T., Rohrer, L., Blyszczuk, P., Shroff, R., Kuschnerus, K., Kränkel, N., Kania, G., Zewinger, S., Akhmedov, A., Shi, Y., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.02.009 · Cited by 310
Self-citationLiver X receptor biology and pharmacology: new pathways, challenges and opportunities
Jakobsson, T., Treuter, E., Gustafsson, J.-Å., & Steffensen, K. R. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.013 · Cited by 302
Some properties of a cholesterol esterifying enzyme in human plasma
Glomset, J. A., & Wright, J. L. (1964) · Biochimica et Biophysica Acta (BBA) - Specialized Section on Enzymological Subjects · doi:10.1016/0926-6569(64)90215-9 · Cited by 299
Westerterp, M., Murphy, A. J., Wang, M., Pagler, T. A., Vengrenyuk, Y., Kappus, M. S., Gorman, D. J., Nagareddy, P. R., Zhu, X., Abramowicz, S., et al. (2013) · Circulation Research · doi:10.1161/circresaha.113.301086 · Cited by 299
Nicholls, S. J., Dusting, G. J., Cutri, B., Bao, S., Drummond, G. R., Rye, K.-A., & Barter, P. J. (2005) · Circulation · doi:10.1161/01.cir.0000159351.95399.50 · Cited by 295
Bloedon, L. T., Dunbar, R., Duffy, D., Pinell-Salles, P., Norris, R., DeGroot, B. J., Movva, R., Navab, M., Fogelman, A. M., & Rader, D. J. (2008) · Journal of Lipid Research · doi:10.1194/jlr.p800003-jlr200 · Cited by 292
Self-citationForrest, M. J., Bloomfield, D., Briscoe, R. J., Brown, P. N., Cumiskey, A., Ehrhart, J., Hershey, J. C., Keller, W. J., Ma, X., McPherson, H. E., et al. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.229 · Cited by 292
Attie, A. D., Kastelein, J. P., & Hayden, M. R. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31498-x · Cited by 284
Control of Cholesterol Turnover in the Mouse
Dietschy, J. M., & Turley, S. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.r100057200 · Cited by 265
Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels
Haghpassand, M., Bourassa, P.-A. K., Francone, O. L., & Aiello, R. J. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12810 · Cited by 256
Mechanisms of Disease: proatherogenic HDL—an evolving field
Navab, M., Anantharamaiah, G. M., Reddy, S. T., Van Lenten, B. J., Ansell, B. J., & Fogelman, A. M. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0245 · Cited by 249
Self-citationApolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma
Huang, R., Silva, R. A. G. D., Jerome, W. G., Kontush, A., Chapman, M. J., Curtiss, L. K., Hodges, T. J., & Davidson, W. S. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2028 · Cited by 246
Control of Cholesterol Metabolism and Plasma High-Density Lipoprotein Levels by microRNA-144
Ramírez, C. M., Rotllan, N., Vlassov, A. V., Dávalos, A., Li, M., Goedeke, L., Aranda, J. F., Cirera-Salinas, D., Araldi, E., Salerno, A., et al. (2013) · Circulation Research · doi:10.1161/circresaha.112.300626 · Cited by 233
Kuvin, J. T., Rämet, M. E., Patel, A. R., Pandian, N. G., Mendelsohn, M. E., & Karas, R. H. (2002) · American Heart Journal · doi:10.1067/mhj.2002.123145 · Cited by 233
ATP binding cassette transporter G1 (ABCG1) is an intracellular sterol transporter
Tarling, E. J., & Edwards, P. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113021108 · Cited by 224
Villines, T. C., Stanek, E. J., Devine, P. J., Turco, M., Miller, M., Weissman, N. J., Griffen, L., & Taylor, A. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.017 · Cited by 223 · cited 1×
“modified lipid profiles, but also reduced plaque formation in carotid and coronary arteries.(89) Unfortunately, the large out-”
Besler, C., Lüscher, T. F., & Landmesser, U. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200224 · Cited by 219
Self-citationLüscher, T. F., Taddei, S., Kaski, J.-C., Jukema, J. W., Kallend, D., Münzel, T., Kastelein, J. J. P., & Deanfield, J. E. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs019 · Cited by 217
Self-citationKimura, T., Tomura, H., Mogi, C., Kuwabara, A., Damirin, A., Ishizuka, T., Sekiguchi, A., Ishiwara, M., Im, D.-S., Sato, K., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605823200 · Cited by 199
Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis
Murphy, A. J., Bijl, N., Yvan-Charvet, L., Welch, C. B., Bhagwat, N., Reheman, A., Wang, Y., Shaw, J. A., Levine, R. L., Ni, H., et al. (2013) · Nature Medicine · doi:10.1038/nm.3150 · Cited by 196
Sphingosine 1-Phosphate (S1P) Carrier-dependent Regulation of Endothelial Barrier
Wilkerson, B. A., Grass, G. D., Wing, S. B., Argraves, W. S., & Argraves, K. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.423426 · Cited by 173
Drew, B. G., Fidge, N. H., Gallon-Beaumier, G., Kemp, B. E., & Kingwell, B. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306266101 · Cited by 169
Goff, W. L., Guérin, M., & Chapman, M. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.10.001 · Cited by 162
Hu, X., Dietz, J. D., Xia, C., Knight, D. R., Loging, W. T., Smith, A. H., Yuan, H., Perry, D. A., & Keiser, J. (2009) · Endocrinology · doi:10.1210/en.2008-1512 · Cited by 150
Watson, C. E., Weissbach, N., Kjems, L., Ayalasomayajula, S., Zhang, Y., Chang, I., Navab, M., Hama, S., Hough, G., Reddy, S. T., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m011098 · Cited by 150
Self-citationInflammation alters HDL composition and function: Implications for HDL-raising therapies
Marsche, G., Säemann, M. D., Heinemann, Á., & Holzer, M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.001 · Cited by 133
Kruit, J. K., Wijesekara, N., Westwell-Roper, C., Vanmierlo, T., de Haan, W., Bhattacharjee, A., Tang, R., Wellington, C. L., LütJohann, D., Johnson, J. D., et al. (2012) · Diabetes · doi:10.2337/db11-1341 · Cited by 117
High Density Lipoprotein Biogenesis, Cholesterol Efflux, and Immune Cell Function
Sorci-Thomas, M. G., & Thomas, M. J. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300135 · Cited by 115
Signaling by the High-Affinity HDL Receptor Scavenger Receptor B Type I
Saddar, S., Mineo, C., & Shaul, P. W. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.196170 · Cited by 109
Terasaka, N., Westerterp, M., Koetsveld, J., Fernández-Hernando, C., Yvan-Charvet, L., Wang, N., Sessa, W. C., & Tall, A. R. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.213215 · Cited by 107
Viswambharan, H., Ming, X.-F., Zhu, S., Hubsch, A., Lerch, P., Vergères, G., Rusconi, S., & Yang, Z. (2004) · Circulation Research · doi:10.1161/01.res.0000124302.20396.b7 · Cited by 104
Structure and Function of HDL Mimetics
Navab, M., Shechter, I., Anantharamaiah, G. M., Reddy, S. T., Van Lenten, B. J., & Fogelman, A. M. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.187518 · Cited by 104
Self-citationTissue-Specific Roles of ABCA1 Influence Susceptibility to Atherosclerosis
Brunham, L. R., Singaraja, R. R., Duong, M., Timmins, J. M., Fievet, C., Bissada, N., Kang, M. H., Samra, A., Fruchart, J.-C., McManus, B., et al. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.182303 · Cited by 102
Insulin-Sensitizing Antihyperglycemic Drugs and Mortality After Acute Myocardial Infarction
Inzucchi, S. E., Masoudi, F. A., Wang, Y., Kosiborod, M., Foody, J. M., Setaro, J. F., Havranek, E. P., & Krumholz, H. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1680 · Cited by 101
Brufau, G., Groen, A. K., & Kuipers, F. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.181206 · Cited by 95
A novel approach to oral apoA-I mimetic therapy
Chattopadhyay, A., Navab, M., Hough, G., Gao, F., Meriwether, D., Grijalva, V., Springstead, J. R., Palgnachari, M. N., Namiri-Kalantari, R., Su, F., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m033555 · Cited by 93
Self-citationCavelier, C., Ohnsorg, P. M., Rohrer, L., & von Eckardstein, A. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.238063 · Cited by 92
Scavenger Receptor Class B Type I Is a Plasma Membrane Cholesterol Sensor
Saddar, S., Carrière, V., Lee, W.-R., Tanigaki, K., Yuhanna, I. S., Parathath, S., Morel, É., Warrier, M., Sawyer, J. K., Gerard, R. D., et al. (2012) · Circulation Research · doi:10.1161/circresaha.112.280081 · Cited by 90
Reverse Cholesterol Transport in Plasma of Patients With Different Forms of Familial HDL Deficiency
von Eckardstein, A., Huang, Y., Wu, S., Funke, H., Noseda, G., & Assmann, G. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.691 · Cited by 86
Self-citationTorcetrapib impairs endothelial function in hypertension
Simic, B., Hermann, M., Shaw, S. G., Bigler, L., Stalder, U., Dörries, C., Besler, C., Lüscher, T. F., & Ruschitzka, F. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr348 · Cited by 85
Self-citationAnacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction
Gutstein, D. E., Krishna, R., Johns, D. G., Surks, H. K., Dansky, H. M., Shah, S., Mitchel, Y., Arena, J. P., & Wagner, J. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.271 · Cited by 76
Navab, M., Reddy, S. T., Lenten, B. J. V., Buga, G. M., Hough, G., Wagner, A. C., & Fogelman, A. M. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300282 · Cited by 76
Self-citationNavab, M., Hough, G., Buga, G. M., Su, F., Wagner, A. C., Meriwether, D., Chattopadhyay, A., Gao, F., Grijalva, V. R., Danciger, J. S., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m042051 · Cited by 72
Self-citationCholesterol Efflux: A Novel Regulator of Myelopoiesis and Atherogenesis
Tall, A. R., Yvan‐Charvet, L., Westerterp, M., & Murphy, A. J. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300134 · Cited by 70
Turner, S., Voogt, J., Davidson, M., Glass, A., Killion, S., Decaris, J., Mohammed, H., Minehira, K., Boban, D., Murphy, E., et al. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.001826 · Cited by 69
Navab, M., Reddy, S. T., Anantharamaiah, G. M., Imaizumi, S., Hough, G., Hama, S. Y., & Fogelman, A. M. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m013144 · Cited by 65
Self-citationNavab, M., Reddy, S. T., Anantharamaiah, G. M., Hough, G., Buga, G. M., Danciger, J. S., & Fogelman, A. M. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m023523 · Cited by 61
Self-citationTanfin, Z., Serrano-Sanchez, M., & Leiber, D. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.07.010 · Cited by 48
Graversen, J. H., Castro, G. R., Kandoussi, A., Nielsen, H., Christensen, E., Norden, A. G. W., & Moestrup, S. K. (2008) · Lipids · doi:10.1007/s11745-008-3169-2 · Cited by 48
Serhan, N., Cabou, C., Verdier, C., Lichtenstein, L., Malet, N., Perret, B., Laffargue, M., & Martinez, L. O. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.12.006 · Cited by 42
Rye, K., & Barter, P. J. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.012 · Cited by 39
Reconstituted HDL in Acute Coronary Syndromes
Chenevard, R., Hürlimann, D., Spieker, L. E., Béchir, M., Enseleit, F., Hermann, M., Flammer, A. J., Sudano, I., Corti, R., Lüscher, T. F., et al. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00221.x · Cited by 37
Self-citationBertrand, O. F., Poirier, P., Rodés‐Cabau, J., Rinfret, S., Title, L. M., Džavík, V., Natarajan, M. K., Angel, J. G. D., Batalla, N., Alméras, N., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.005 · Cited by 34
von Eckardstein, A. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.6 · Cited by 32
PON-dering differences in HDL function in coronary artery disease
Mineo, C., & Shaul, P. W. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57671 · Cited by 31
Silvennoinen, R., Escolá‐Gil, J. C., Julve, J., Rotllán, N., Llaverías, G., Metso, J., Valledor, A. F., He, J., Yu, L., Jauhiainen, M., et al. (2012) · Circulation Research · doi:10.1161/circresaha.112.277962 · Cited by 28
Landmesser, U. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht064 · Cited by 21
Self-citationmicroRNAs: small regulators with a big impact on lipid metabolism
Moore, K. J. (2013) · Journal of Lipid Research · doi:10.1194/jlr.e036954 · Cited by 18
Mulling over the odds of CETP inhibition
von Eckardstein, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp394 · Cited by 11
Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease
OLSSON, A. G. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.489894 · Cited by 10
Tachometer for Reverse Cholesterol Transport?
von Eckardstein, A. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.003723 · Cited by 8
Cited by
Endothelial dysfunction and vascular disease - a 30th anniversary update
Vanhoutte, P. M., Shimokawa, H., Feletou, M., & Tang, E. H. C. (2017) · Acta Physiologica · doi:10.1111/apha.12646 · Cited by 937
“However, HDL of patients with coronary artery disease lose their protective properties and rather become inhibitors of eNOS (Besler et al. 2011, Gomaraschi et al. 2013, Tran-Dinh et al. 2013, Kratzer et al. 2014, Luscher et al. 2014).”
BackgroundHDL and cardiovascular disease
Rader, D. J., & Hovingh, G. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61217-4 · Cited by 870
Dysfunctional HDL and atherosclerotic cardiovascular disease
Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.124 · Cited by 822
Evacetrapib and cardiovascular outcomes in high-risk vascular disease
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801
Anti-inflammatory therapies for cardiovascular disease
Ridker, P. M., & Luscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu203 · Cited by 550
Metadata
- Authors
- Lüscher, T. F., Landmesser, U., von Eckardstein, A., & Fogelman, A. M.
- Venue
- Circulation Research
- Published
- 2014-01-03
- Volume
- 114
- Issue
- 1
- Pages
- 171-182
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W1964872560
- Cited by
- 291
- References
- 111
- FWCI
- 38.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.